Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.5459
+$0.0017 · +0.31%
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Regular session
$0.5459
+$0.0017 · +0.31%
Regular session · ET · Market data may be delayed.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Day range
Current $0.5459
52-week range
Current $0.5459
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
39
Bearish
Risk
85
Extreme Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Day range
Current $0.5459
52-week range
Current $0.5459
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 8.44M USD | 8.47M USD | 8.69M USD | 8.71M USD | 4.03M USD |
| Gross profit | −8.44M USD | −8.47M USD | −8.69M USD | −8.71M USD | −4.03M USD |
| Research and development | 68.61M USD | 86.74M USD | 98.04M USD | 94.54M USD | 54.39M USD |
| Selling, general, and administrative | 24.72M USD | 20.74M USD | 24.47M USD | 22.37M USD | 14.39M USD |
| Operating expenses | 84.9M USD | 107.48M USD | 122.51M USD | 116.91M USD | 68.78M USD |
| Interest income | 2.68M USD | 4.74M USD | 7.06M USD | 1.95M USD | 108K USD |
| Depreciation and amortization | 8.44M USD | 8.47M USD | 8.69M USD | 6.47M USD | 2.96M USD |
| Operating income | −93.33M USD | −115.95M USD | −131.19M USD | −125.62M USD | −72.81M USD |
| Net income | −90.6M USD | −111.13M USD | −124.08M USD | −123.67M USD | −72.72M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.33
326.82% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.53M0.00%2.3T USD0.03%$381.28+0.45%
Vanguard Extended Market ETFVXF1.22M0.00%95.4B USD0.05%$234.7+0.67%
iShares Biotechnology ETFIBB890.08K0.01%10.41B USD0.44%$204.24+1.88%
Invesco RAFI US 1500 Small-Mid ETFPRFZ158.74K0.01%2.65B USD0.36%$53.145+0.62%
Invesco NASDAQ Future Gen 200 ETFQQQS93.02K0.41%22.71M USD0.20%$41.89+0.77%
Invesco Nasdaq Biotechnology ETFIBBQ8.45K0.01%109.47M USD0.19%$34.225+1.78%
ProShares Ultra Nasdaq BiotechnologyBIB4.3K0.00%88.27M USD1.19%$108.75+3.55%
Avantis Total Equity Markets ETF 1AVTM1.96K—790.12M USD0.23%$55.29640.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAvantis Total Equity Markets ETF 1AVTMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
